Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1995 Apr 15;51(4):343-8.
doi: 10.1007/BF01928892.

Suppression of natural killer cell activity in mouse spleen lymphocytes by several dopamine receptor antagonists

Affiliations

Suppression of natural killer cell activity in mouse spleen lymphocytes by several dopamine receptor antagonists

S J Won et al. Experientia. .

Abstract

The effects of dopaminergic receptor inhibitors such as thiothixine (D1/D2), fluphenazine (D1/D2), trifluoperazine (D1/D2), pimozide (D2), flupenthixol (D1/D2), (+/-)-SKF 83566 (D1), and spiperone (D2) on splenic natural killer (NK) cell cytotoxic activities were assessed in vitro using mouse spleen lymphocytes or enriched NK cells. Both the activities of the splenic NK cell cytotoxicity and the effector-target cell conjugation were suppressed by thiothixine, fluphenazine, and trifluoperazine at concentrations from 2.64 to 14.78 microM. In addition, the augmentation of the cytolytic activity of NK cells induced by interferon-alpha or interleukin-2 was antagonized by pretreatment with these neuroleptic compounds. However, neither the splenic NK cell cytotoxicity nor the effector-target cell conjugation were affected by treatment with other neuroleptic compounds such as pimozide, flupenthixol, (+/-)-SKF 83566, and spiperone. Thus, it appears that neuroleptic compounds such as thiothixine, fluphenazine, and trifluoperazine may act through the mechanisms other than a dopaminergic pathway to affect the NK cell-target cell interaction.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Infect Immun. 1979 Oct;26(1):49-56 - PubMed
    1. J Exp Med. 1989 Nov 1;170(5):1757-61 - PubMed
    1. Cell Immunol. 1984 Sep;87(2):411-23 - PubMed
    1. J Immunol. 1983 Feb;130(2):981-7 - PubMed
    1. J Immunol. 1985 Jun;134(6):4095-9 - PubMed

Publication types

MeSH terms